Trial Profile
Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Jul 2023 Time frame changed from 2 years to Up to 9 months.
- 19 Jul 2023 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Status changed from recruiting to active, no longer recruiting.